TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05346731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
Study: NCT05767437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal drawing-in maneuver exercise
Description: From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal drawing-in maneuver exercise
Description: From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham
Description: Release pain or upper limb mobilization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham
Description: Release pain or upper limb mobilization
Study: NCT05102734

Intervention type: DRUG
Intervention: Nitroglycerin Topical Product
Description: Topical nitroglycerin solution
Study: NCT06526247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength at Home (SAH)
Description: SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual for IPV
Description: Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
Study: NCT05630638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
Study: NCT05171686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
Description: The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
Study: NCT05473039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seidivid Ferty4
Description: The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
Study: NCT04981717

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: SC for a total of 5 administrations
Study: NCT06306300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Specialist - Epclusa 400Mg-100Mg Tablet
Description: HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by a specialized doctor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non- specialist - Epclusa 400Mg-100Mg Tablet
Description: HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
Study: NCT06377488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter
Description: Test Lens
Study: NCT05705557

Intervention type: DEVICE
Intervention: ABSOLOK™ Clip System
Description: Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
Study: NCT05997212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive high frequency 10 Hz stimulation at 100% of motor threshold over the dorsolateral prefrontal cortex (DLPFC) at 1500 pulses per session with 30 trains of 5 seconds and 0.5 ms stimuli and an inter-train distance of 15 seconds. In 2 daily sessions 4 days a week for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Sham)
Description: The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive consistent treatment in 2 sessions a day for 20 consecutive business days for 4 weeks. The coil will be placed facing away from the skull to avoid an effect.
Study: NCT05332132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heracure Device
Description: Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
Study: NCT05310981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCanChange
Description: iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
Study: NCT04623008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Oriented Episodic Future Thinking
Description: Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
Study: NCT04786782

Intervention type: DIAGNOSTIC_TEST
Intervention: PPG-detecting software
Description: Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: LSM and PLT count
Description: Patients whose LSM \>15kPa, or PLT count \< 150\*10\^9 should be screened with upper GI endoscopy
Study: NCT06248762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adappt
Description: An app to support parents of children with a NDD

Intervention type: OTHER
Group type: OTHER
Intervention: Adappt
Description: An app to support parents of children with a NDD
Study: NCT04543526

Intervention type: DEVICE
Intervention: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Description: Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
Study: NCT06261658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryopreserved Ovarian Tissue Reimplantation
Description: Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Study: NCT06065371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govetican
Description: Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5.
Study: NCT05166161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
Study: NCT06425471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KARL STORZ fetoscope arm
Description: The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
Study: NCT05859334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Undergo OCT
Study: NCT04920097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person training for seed placement and APA
Description: In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual training for seed placement and APA
Description: Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will continue with usual care from oncologist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-training zoom session for seed placement and APA coaching
Description: Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-training zoom session for seed placement and APA coaching
Description: Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).
Study: NCT04697719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: 81mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: 81mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: 325mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: 325mg oral capsule
Study: NCT05782777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
Description: The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity statin monotherapy (atoravastatin 40mg)
Description: The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
Study: NCT06256744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Resistance exercise
Study: NCT05385055

Intervention type: OTHER
Intervention: THS use
Description: N/A: No intervention was assigned.

Intervention type: OTHER
Intervention: Cigarette smoking
Description: N/A: No intervention was assigned.

Intervention type: OTHER
Intervention: Smoking abstinence
Description: N/A: No intervention was assigned.
Study: NCT06369116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTI HCV Self Test
Description: Each participant will be presented with a packaged self-test and asked to conduct self testing. The Trained Observer will only watch the participant process at a short distance and take notes on the process; at no point will the observer respond to questions or assist with the testing process - only to encourage the participant to try to figure out the process as best they can use the instruction sheet.~The participant will then be permitted to perform the self-test and read their self test result. The observer is also going to observe the test result interpreted by the lay user and also themselves. After this step is complete, the Trained Observer will then perform fingerstick sample collection from lay user and run the sample on INSTI® HCV Self Test. The Trained Observer will then draw a venous whole blood sample from the participant for laboratory testing and final diagnosis will be given to the participant once laboratory results have been received.
Study: NCT05710848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STM-416
Description: STM-416 monotherapy
Study: NCT06524908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and dietary calorie restriction
Description: The intervention group received an exercise intervention three times a week (resistance exercise from 4:30-5:00 p.m. and aerobic exercise from 5:00-5:30 p.m.), and a caloric restriction intervention (guided semi-libre diet with caloric intake restricted to 75% of overall consumption, with parents keeping track of calories and food groups and receiving regular check-ups)
Study: NCT05716360

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
Description: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
Description: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
Study: NCT06526026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual crisis stabilization support with a multi-disciplinary team
Description: Daily 1:1 sessions with multidisciplinary team via a range of virtual modalities (videoconferencing, phone, text, email), group programming, self-management resources, remote home monitoring app, referrals and linkages to community programs.
Study: NCT04356976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventralex
Description: Repair of hernia using Ventralex patch in sublay position
Study: NCT05716360

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
Description: Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device

Intervention type: PROCEDURE
Intervention: Aneurysm Treatment with Flow-Diversion Therapy
Description: Aneurysm Treatment with Flow-Diversion Therapy

Intervention type: PROCEDURE
Intervention: Aneurysm Treatment with Flow-Diversion Therapy
Description: Aneurysm Treatment with Flow-Diversion Therapy

Intervention type: PROCEDURE
Intervention: Aneurysm Treatment with Metalic Bare Stent
Description: Aneurysm Treatment with Metalic Bare Stent
Study: NCT04356976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stratafix
Description: Repair of hernia without mesh. Defect closed with Stratafix suture.
Study: NCT05574959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: investigational IOL Model DEN00V
Description: Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control IOL Model ZCB00/DCB00
Description: Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
Study: NCT05466331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Tele-HCV Care
Description: Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Study participants are referred to a clinician in their area for HCV care.
Study: NCT06363539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION
Description: steroid used for umblical granuloma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nitrate
Description: silver nitrate used for treatment
Study: NCT05672550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bayesian based dose adjustment of enoxaparin
Description: A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual dose adjustment of enoxaparin
Description: A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
Study: NCT05799417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic stimuli
Description: During different states of sedation/anaesthesia and sleep, acoustic stimuli will be presented and compared to a within-subject baseline.
Study: NCT05678257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosifloxuridine Nafalbenamide
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosifloxuridine Nafalbenamide
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Intravenous infusion
Study: NCT05370443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills education program
Description: The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations.